Internal Medicine, Rheumatology · Green Bay, WI
NPI
1023243805
Since 2009
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2223 Lime Kiln Rd, Ste 1
Green Bay, WI, 54311
Phone (920) 430-8120
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
72,512 services
Medicare patients, 2024
404
Average age 71
Drug cost, 2024
$3.7M
5,329 prescriptions
Company payments, 2025
$1,106
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul V Tuttle IV was code J3262 (injection, tocilizumab, 1 mg), 26,240 times for 15 patients. In total Paul V Tuttle IV billed 72,512 services in 68 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 26,240 | 15 | $4.68 | $123K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 12,651 | 31 | $9.00 | $114K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 11,050 | 40 | $33.23 | $367K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 8,016 | 66 | $24.74 | $198K |
| J0897 Injection, denosumab, 1 mg | Office | 1,860 | 21 | $20.48 | $38K |
| J9312 Injection, rituximab, 10 mg | Office | 1,700 | 11 | $61.34 | $104K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 733 | 21 | $0.23 | $168 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 512 | 177 | $0.51 | $261 |
| 99214 Office E&M - Established | Office | 423 | 255 | $88.11 | $37K |
| 96365 Intravenous Infusion, Hydration | Office | 251 | 87 | $47.42 | $12K |
| 96413 Chemotherapy Administration | Office | 243 | 100 | $94.71 | $23K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 239 | 169 | $11.62 | $2,778 |
| A9577 Injection, gadobenate dimeglumine (multihance), per ml | Office | 229 | 12 | $1.43 | $327 |
| 96415 Chemotherapy Administration | Office | 196 | 79 | $20.79 | $4,076 |
| 96375 Injection Administration | Office | 105 | 33 | $11.64 | $1,222 |
By year: 2022 $905K for 56,230 services; 2023 $1.1M for 67,409 services; 2024 $1.3M for 72,512 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 35 | 27 | $8.65 | $303 |
Medicare prescription drug claims, 2024
In 2024, the drug Paul V Tuttle IV prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 989 prescriptions and refills. In total Paul V Tuttle IV wrote 5,329 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 989 | 2,312 | 255 | $35K |
| Methotrexate Methotrexate Sodium | 958 | 2,235 | 253 | $24K |
| Prednisone Generic | 637 | 1,219 | 186 | $5,925 |
| Folic Acid Generic | 227 | 570 | 58 | $2,386 |
| Sulfasalazine Generic | 206 | 410 | 58 | $6,081 |
| Alendronate Sodium Generic | 180 | 460 | 64 | $1,762 |
| Omeprazole Generic | 176 | 477 | 63 | $1,999 |
| Leflunomide Generic | 176 | 393 | 46 | $8,518 |
| Tramadol Hcl Generic | 152 | 158 | 42 | $1,663 |
| Methylprednisolone Generic | 149 | 210 | 78 | $2,669 |
| Gabapentin Generic | 133 | 256 | 39 | $2,398 |
| Humira(Cf) Pen Adalimumab | 125 | 136 | 16 | $1.6M |
| Allopurinol Generic | 109 | 292 | 32 | $2,179 |
| Meloxicam Generic | 102 | 246 | 32 | $510 |
| Colchicine Generic | 62 | 105 | 21 | $6,098 |
Brand drugs: - claims; generic drugs: 4,637 claims; opioid claims: 191.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul V Tuttle IV $1,106 ($1,106 in general payments such as food, travel and fees) from 12 companies. The largest payer was Abbvie Inc. with $414.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 24 | $414 |
| Genzyme Corporation SNY | 1 | $148 |
| Amgen Inc. AMGN | 2 | $129 |
| Janssen Biotech, Inc. JNJ | 1 | $100 |
| Lilly USA, LLC LLY | 3 | $64.24 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $56.3 |
| Pfizer Inc. PFE | 2 | $55.35 |
| UCB, Inc. UCB.BR | 1 | $34.54 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $31.91 |
| TG Therapeutics, Inc. TGTX | 1 | $27.91 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.